ERBB2 is a transmembrane tyrosine kinase receptor encoded by a gene located in chromosome region 17q12. Overexpression of ERBB2, generally by way of gene amplification, plays a role in mammary oncogenesis. This alteration can be overcome by use of the humanized monoclonal antibody trastuzumab (Herceptint). Accurate determination of ERBB2 status is required for appropriate use of this targeted therapy and is currently analysed by immunohistochemistry (IHC) on tissue sections and/or fluorescence in situ hybridisation (FISH) on interphase chromosomes. We have studied the gene expression profiles of a series of 213 breast tumours and 16 breast cancer cell lines with known ERBB2 status, using Ipsogen's DiscoveryChip microarrays with B9000 cDNAs. We have identified 36 genes and expressed sequence tags that were differentially expressed in tumours and in cell lines with and without ERBB2 protein overexpression. This ERBB2-specific gene expression signature (GES) contained 29 overexpressed genes including the ERBB2 gene itself, five genes located in its immediate vicinity on 17q12, non-17q genes such as GATA4 and eight downregulated genes including oestrogen receptor a (ER). Some correlations were validated at the protein level using IHC on tissue microarrays. The
Introduction
The ERBB2 oncogene, also called HER2 or NEU, is located in band q12 of chromosome 17 (http://www. ensembl.org/). It codes for a 185-kDa transmembrane tyrosine kinase related to members of the ERBB/EGFR family. ERBB2 is amplified and overexpressed in 15-30% of breast cancers (Slamon et al., 1987) . Although its exact role in mammary oncogenesis remains unclear (Holbro et al., 2003, for review) , the receptor is a clinically relevant target for the treatment of disease for two reasons. First, ERBB2 gene amplification and overexpression of ERRB2 gene products have been associated with prognosis or response to anticancer therapies (for a review, see Hayes and Thor, 2002) . Second, therapy based on a humanized monoclonal anti-ERBB2 antibody (trastuzumab/Herceptint) has shown benefits in metastatic patients (for a review, see Leyland-Jones, 2002) . However, modifications of chemotherapy and hormonal therapy strategies based on ERBB2 status remain controversial.
Currently, ERBB2 status is primarily determined by two different methods: fluorescence in situ hybridization (FISH), which reveals gene amplification, and immunohistochemistry (IHC), which detects the overexpressed protein (for recent reviews, see: Rampaul et al., 2002; Bilous et al., 2003) . FISH is a good method for ERBB2 testing but is technically more difficult to implement than IHC, which is easier to perform but difficult to standardize (Pauletti et al., 2000) . IHC is currently the only FDA-approved test for selection of patients for treatment with trastuzumab, and American Society for Clinical Oncology and National Comprehensive Cancer Network guidelines recommend the use of either FISH or the HercepTestt, a specific IHC test made by the Dako Corporation. This method semiquantitatively assesses positive staining on a scale ranging from 0 (absence of ERBB2 protein overexpression) to 3 þ (maximum of overexpression). For pathologists, interpretation of results is relatively straightforward in ERBB2-negative individuals (0-1 þ ) and in patients who strongly overexpress the protein (3 þ ), but proble-matic for cases with intermediate level 2 þ ; for the latter (10-15% of all breast cancers), the concordance with FISH is, at best, 25%. Importantly, a proportion of 2 þ cases are bona fide ERBB2-overexpressing tumours to which Herceptin treatment should be applied. Thus, accurate and standardized determination of ERBB2 status has not yet been achieved. The reliability of this determination will greatly influence the selection of the relevant cases and thus the efficacy of Herceptin. Moreover, specific methods for patient selection for ERBB2 antagonists may serve as a paradigm for guiding clinical use of the new targeted approaches expected in the near future. It is thus important to further document the methods and parameters useful to assess ERBB2 status.
Clinical outcome may vary between patients with the same ERBB2 status and treatment, implying that other factors may play a role in determining the level of sensitivity to trastuzumab. It may be necessary to associate other targeted therapies to anti-ERBB2 treatment and identification of complementary or secondary targets may prove useful. Although the common pathways such as the RAS/MAPK pathway and other induced genes have been reported (Oh et al., 1999) , ERBB2-associated signalling cascades have yet to be elucidated. Thus, accurate measurement of ERBB2 status, as well as identification of associated molecular alterations are now intensively required.
Emerging technologies may facilitate progress on both ERBB2 typing and target discovery. Among these, DNA microarrays are currently prominent (for reviews, see Bertucci et al., 2003a, b) . This technology can be used to improve the prognostic classification of breast cancers (Golub et al., 1999; Bertucci et al., 2000; Perou et al., 2000; Sorlie et al., 2001; Bertucci et al., 2002; Van't Veer et al., 2002; Sorlie et al., 2003) . Here, we have analysed 213 breast carcinomas and 16 breast cell lines using DNA microarrays containing B9000 spotted PCR products from known genes and expressed sequence tags (ESTs). Our aim was to identify differences in gene expression patterns between ERBB2-negative and ERBB2-positive breast tumours. Using both supervised and unsupervised analyses, we have identified a series of 37 discriminator genes/ESTs called 'ERBB2 gene expression signature', the expression of which permitted to distinguish ERBB2-negative and -positive samples, as well as FISH-negative and FISH-positive ERBB2 2 þ samples. Among the genes included in the signature were potential additional targets, such as GATA4, which was validated at the protein level using tissue microarray (TMA) of breast cancers.
Results

Identification and validation of an ERBB2 gene expression signature (GES) from tumour profiling
Supervised analysis was utilized to identify a GES correlated with ERBB2 status. It was applied to the mRNA expression profiles from 145 randomly chosen breast cancer samples (learning set), by comparing two subgroups defined by their ERBB2 status as determined by standard IHC: samples scoring 0 and 1 þ (hereafter designated ERBB2À, 116 samples) were compared to samples scoring 3 þ (ERBB2 þ , 29 samples). At this stage, cases with equivocal 2 þ (n ¼ 10) or unavailable (n ¼ 4) staining were excluded from analysis. To identify a molecular signature independent from the predefined subgroups of tumours, we iteratively defined several different subsets of samples and performed supervised analysis on each of these subsets independently. A total of 30 such iterations were carried out. The lists of genes identified as significant discriminators (these lists ranged from 80 to 274 clones) were then compared, revealing 37 clones present in at least 25 lists: all these clones were tag-resequenced to confirm their identity and defined our ERBB2-specific GES. Figure 1 shows the expression pattern of this signature in the 145 samples in a colour-coded matrix. Samples are classified according to their correlation coefficient with the ERBB2 þ group. As shown, the resulting discrimination between ERBB2 þ and ERBB2À samples was successful with only two misclassifications. The 37 clones corresponded to 36 unique sequences (two different clones represented ERBB2) representing 29 characterized genes and seven other sequences or ESTs. In all, 29 were overexpressed and eight were underexpressed in ERBB2 þ samples. Their identity and chromosomal location are listed in Figure 1 .
We next validated our GES in an independent set of 54 breast cancer samples (validation set, 46 ERBB2À and eight ERBB2 þ ). As shown in Figure 2a , classification of samples based on the GES successfully classified them according to ERBB2 IHC status with only one ERBB2À sample misplaced in the ERBB2 þ group.
Validation of the ERBB2 GES from profiling of breast tumour cell lines
We profiled a series of 16 breast cancer cell lines that included five cell lines (BT-474, HCC1569, MDA-MB-453, SK-BR-3 and UACC-812) known to have amplification and/or high mRNA expression of the ERBB2 gene (Kauraniemi et al., 2001; Wilson et al., 2002) . ERBB2 GES successfully separated ERBB2 þ and ERBB2À cell lines (Figure 2b) .
Collectively, these analyses demonstrated that our ERBB2 GES correctly classified breast tumours and cell lines consistent with ERBB2 status evaluated with a standard procedure (Herceptestt).
Analysis of breast tumour samples using tissue microarrays
Significant discriminator genes were further validated by immunohistochemical analysis of their corresponding proteins (Figure 3a) . A total of B250 cases from TMA1 were available for the study of ERBB2, oestrogen receptor a (ER, encoded by the ESR1 gene), GATA4 and Ki67. In ERBB2 GES, ERBB2, GATA4 and Ki67 genes were overexpressed and ESR1 was underexpressed in ERBB2 þ samples. These correlations were confirmed at the protein level: overexpression of ERBB2 protein was significantly associated with an upregulation of GATA4 (Po0.001), Ki67 (Po0.025), and with negativity of ER (Po0.0001) ( Table 1) . We found 40% of ERBB2 þ tumours in ER-negative tumours but only 10% in ER-positive tumours.
A total of 68 (72%) of the 94 samples included in TMA2 were available for FISH analysis of ERBB2 locus. Examples of results are shown in Figure 3b . Of the 68 cases, 30 displayed ERBB2 amplification, whereas 38 were not amplified.
Classification of breast tumours using ERBB2 GES
Previous supervised analyses did not include the breast cancer samples with 2 þ (n ¼ 10) or unavailable (n ¼ 4) status for ERBB2 IHC. We reclassified them with all 145 samples previously analysed -which included the 68 cases with available FISH ERBB2 data -by using hierarchical clustering program based on ERBB2 GES. Results are displayed in Figure 4 that highlights clusters of correlated genes across clusters of correlated samples. The first large gene cluster contained 29 genes/ESTs, including ERBB2 (it was designated 'ERBB2 cluster'). The second gene cluster was globally negatively correlated with the previous one: it contained eight genes/ ESTs, including ESR1 (it was designated 'ER cluster').
Despite transcriptional heterogeneity between tumours for these genes, the combined expression patterns defined at least three groups of tumours, designated A, B and C. Group A (73 cases, green branches of the dendrogram) displayed an overexpression of the 'ER cluster' and an underexpression of the 'ERBB2 cluster' overall compared to groups B and C. Conversely, the 'ERBB2 cluster' and the 'ER cluster' were upregulated and downregulated in group C samples (36 cases, red branches) overall, as compared to other groups. Finally, group B (50 cases, black branches) displayed an intermediate profile with heterogeneous expression of the 'ERBB2 cluster' and underexpression of the 'ER cluster'.
Correlations of tumour groups with ERBB2 status were analysed. As expected, group C strongly differed from the other groups with respect to ERBB2 protein expression since 93% of all ERBB2 3 þ samples were located in this group. In group C, 77% of samples scored 3 þ , 9% 2 þ and 14% 0-1 þ ; in contrast, in groups A and B, these rates were 0 and 5% (3 þ ), 3 and 10% (2 þ ), and 97 and 85% (0-1 þ ) (Po0.0001, w 2 test, A vs B vs C groups), respectively. There was a strong ) from TMA1 containing 552 tumours and control samples. Two examples of IHC staining for ERBB2, Ki67, ER and GATA4 are shown below. Case 1 shows a tumour sample with no detected ERBB2 expression, no Ki67 expression, strong ER expression equal to Q ¼ 300 and no GATA4 expression. Case 2 shows a tumour sample with ERBB2 overexpression equal to 3 þ , a Ki67 expression equal to P ¼ 20, no ER expression and a GATA4 overexpression equal to Q ¼ 300. (b) Analysis of ERBB2 gene copy number in breast tumours using FISH on tissue microarray sections. On top, HES of paraffin block section (25 Â 30 mm 2 ) from TMA2 containing 94 tumours. Below, two sections of invasive breast carcinomas are shown, the first with ERBB2 amplification and the second with normal gene copy number. Red dots (arrows) represent ERBB2 copies and green dots represent centromere 17, on interphase chromosomes Table 1 Validation of GES using TMA1 for three non-17q-encoded proteins present in the signature correlation between tumour groups and FISH status with most of the FISH-positive cases clustered in group C (Po0.0001, w 2 test, A vs B vs C groups). ERBB2 FISH information and IHC status were both available in 64 cases out of 159. Interestingly, the three 2 þ tumours located in group C displayed ERBB2 amplification (FISH positive), while the seven 2 þ tumours included in groups A (two cases) and B (five cases) had no amplification (FISH negative). Our ERBB2 GES could separate FISH-positive and FISH-negative ERBB2 2 þ tumours, providing more specific information with respect to FISH status as compared with ERBB2 IHC status (HercepTest). Indeed, the correlation between GES groups (C samples vs A þ B samples) and FISH result (negative vs positive) provided a sensitivity of 90% and a specificity of 88% (concordance in 89% of cases). In comparison, the correlation between IHCbased grouping (0-1 þ vs 2-3 þ ) and FISH status showed an equal sensitivity of 90% but a weaker specificity of 76% (concordance in 82% of cases) ( Table 2) . Sensitivity was even probably better for the two comparisons; as shown in Figure 4 , two samples located in groups A and B and IHC negative for ERBB2 were FISH positive; reviewing of the corresponding sections revealed in fact the presence of intraductal carcinoma in one case and abundant necrosis in the other case, both of which might have lead to false positive FISH results. Further verification using realtime quantitative PCR definitely demonstrated the absence of ERBB2 amplification (not shown). Taken into account the two samples with false-positive FISH results, the error rate was five out of 64 (with four false positive and one false negative) for correlation between our classification and FISH, whereas it was nine out of 64 for correlation between standard IHC and FISH.
Correlation with histoclinical parameters
We searched for correlations between tumour groups and relevant molecular and histoclinical parameters of samples. As expected (Revillion et al., 1998), our Figure 1 for colour scheme). Dendrograms of samples (above data matrix) and genes (to the left of matrix) represent overall similarities in expression profiles. The orange vertical lines mark the subdivisions into three main tumour groups that are represented in the branches of dendrogram in green (A), black (B) and red (C), respectively. The dendrogram of genes is zoomed in (b). Between the dendrogram of samples and the data matrix are represented, according to a grey colour ladder relevant, histoclinical data for the tumours: ERBB2 IHC (HercepTest: 0-1 þ , white; 2 þ , light grey; 3 þ , black; unavailable; dark grey) and FISH (negative, white; positive, black; unavailable, dark grey) status, SBR grade (I, white; II, light grey; III, black; unavailable, dark grey), ER, PR and P53 IHC status (negative, white; positive, black, unavailable, dark grey), axillary lymph node invasion (negative, white; positive, black), pathological size of tumours (pT1, white; pT2, light grey; pT3, black). (b) Dendrogram of genes referenced by their HUGO abbreviation. Genes/ESTs located on 17q are marked with *. See the 'ERBB2 cluster' (red branches) and the 'ER cluster' (green branches) 
Content of the ERBB2 GES
In total, 29 genes/ESTs were significantly overexpressed in ERBB2 þ tumours. Their coexpression may indicate coamplification (same chromosomal location), regulation by ERBB2, coregulation by common factors or association with unknown phenotypic feature of disease. In addition to ERBB2 itself, there were six genes from region q12 of chromosome 17 in the signature ( Figure 1) ; the six genes are all located within less than one megabase on either side of ERBB2, defining a small 'core' region of coexpressed -probably coamplifiedgenes ( Figure 5 ). Genes from 17q12 that were absent from the microarray (e.g. MLN64/STARD3) are not shown in Figure 5 . Although overexpression of 17q genes with ERBB2 is likely to be due simply to DNA amplification, the functional affect of overabundant transcripts of these genes may impact on the clinical outcome in patients. Indeed, this may be the case for example for GRB7 or PPARBP. GRB7, a tyrosine kinase cytoplasmic adaptor substrate, has been implicated with different partners in integrin-mediated cell migration (Shen et al., 2002) . PPARBP has been shown to downregulate P53-dependent apoptosis (Frade et al., 2002) . Other genes from the microarray and located on 17q but further apart from ERBB2 were not found in the signature except for ITGA2B/CD41, ITGB3/CD61, PECAM1/CD31 and MAP2K6. Overexpression of these genes may not be due to increased ERBB2 gene copy number per se, but may be triggered by intense ERBB2 signalling; it might also be due to the presence of other telomeric, 17q-associated amplicons (Andersen et al., 2002; Hyman et al., 2002) . ITGA2, whose gene is not on 17q, was also overexpressed in ERBB2 þ tumours.
There may be a whole group of loci whose transcription is coordinately increased because the corresponding proteins belong to the same network. In total, four genes expressed in endothelial cells and platelets (encoding three integrins ITGA2, ITGA2B, ITGB3, and an adhesion molecule of the Ig family PECAM1) were overexpressed in ERBB2 þ tumours (however, not all integrin genes from 17q present on the microarray were overexpressed since ITGA3 was not). Overexpression of these genes may be associated with a specific (e.g. either ER negative, basal-like or neoangiogenic) phenotype. Other genes in the near vicinity of ERBB2 locus may be coamplified with ERBB2 gene, but may not be expressed due to the absence of an appropriate promoter or to repression. While amplification greatly influences gene expression (Pollack et al., 2002) , only a proportion of genes from a given amplicon are overexpressed (Platzer et al., 2002) .
Other overexpressed genes were not located on chromosome arm 17q. CDH15, also called M-Cadherin or muscle cadherin, is expressed in myoepithelial cells. It might suggest that ERBB2 þ tumours have a certain degree of myoepithelial differentiation; alternatively, they may be characterized by a high degree of dedifferentiation with appearance of new markers. An interesting finding was GATA4, whose coexpression with ERBB2 was validated at the protein level. This gene codes for a transcription factor of the GATA family (Patient and McGhee, 2002) . GATA4 is essential for cardiovascular development (Kuo et al., 1997) , and may regulate genes critical for myocardial differentiation and function. Likewise, ERBB2 is essential for heart development (Garratt et al., 2003, for review) . It is therefore possible that ERBB2 exerts some of its downstream effects through GATA4 or alternatively, that GATA4 stimulates ERBB2 gene transcription. Incidentally, MAP2K6 is also strongly expressed in cardiac muscle (Han et al., 1996) . The major adverse effect of Herceptin is cardiotoxicity. Investigation of the functional relationship between ERBB2, GATA4 and MAP2K6 may enhance current understanding of cardiotoxicities associated with ERBB2 antagonists, and contribute to design ways to circumvent this side effect. Activation of GATA4 is thought to occur through RHO GTPases (Yanazume et al., 2002) , which are also central to the functions of integrins and cadherins (for a review, see Arthur et al., 2002) . Figure 5 Localization of genes from chromosome 17q12-24 region represented on the DNA microarray. Genes identified in our ERBB2 GES and with expression upregulated in our ERBB2 þ breast cancer samples are indicated in bold. The other genes indicated were represented on the microarray but were not found in the ERBB2 signature. The list of genes is not thorough for genes located outside 17q12. From several studies, we can point to a 'core' of genes almost always cooverexpressed with ERBB2. @: gene cluster
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The MKI67 gene encodes the proliferation marker Ki67/MIB1. It was upregulated in ERBB2 þ samples, suggesting that ERBB2 þ tumours are proliferative tumours. Immunohistochemical results on B250 TMA1 tumours for ERBB2 and Ki67 staining confirmed such correlation at the protein level in agreement with recent reports (Korsching et al., 2002; Callagy et al., 2003) . The overexpression of the CSTA gene, which encodes cystatin A, a cysteine protease inhibitor of the stefin family that acts as endogenous inhibitor of cathepsins, may be put in perspective with the finding of Oh et al. (1999) on the downregulation of cathepsin D in ERBB2-transfected MCF7 cells. Finally, the presence of genes encoding two structurally related factors, lymphotoxin A (LTA) and preB-cell colony-enhancing factor (PBEF), and NFKBIE imply that specific immune and inflammatory mechanisms may be associated with ERBB2 þ tumours.
Only five genes with known function were downregulated in ERBB2-positive tumours. Interestingly, one of these was ESR1, which encodes ER a. It is recognized that most ERBB2-amplified tumours are ER negative and resistant to hormone therapy (Keshgegian, 1995; Konecny et al., 2003) . Moreover, an interplay between ERBB2 and ER pathways has been demonstrated (Pietras et al., 1995) . There were also SCUBE2, a gene encoding a secreted protein with an EGF-like domain (Yang et al., 2002) , and CELSR2, which encodes a nonclassical cadherin. These two molecules might have antagonistic regulatory roles of ERBB2 activities at the cell membrane. SCUBE2 and NAT1 were associated to ESR1 in GES associated with ER positivity (Sorlie et al., 2003 ; personal data).
Discussion
In this work, we have defined a set of genes that discriminate between ERBB2 þ and ERBB2À breast tumours. The identity of these genes may give insight in the underlying biological mechanisms associated with ERBB2 status and with the aggressive phenotype of ERBB2 þ breast cancers. They may also provide new diagnostic, prognostic and predictive factors, as well as new therapeutic targets. Some of the genes in the signature reported in this study are known to be associated with ERBB2 and cancer, while others constitute new associations. Two issues need to be further discussed: the inclusion of these discriminator genes in similar studies and the interest of using GES for the determination of ERBB2 status.
ERBB2 and microarrays
Several recent large-scale gene expression studies have addressed the issue of ERBB2 status and function in breast cancer. A large-scale study of the ERBB2 amplicon was carried out on seven breast tumour cell lines by Kauraniemi et al. (2001) using a microarray that included 217 cDNAs from 17q12 genes; ERBB2, GRB7, PPP1R1B were consistently overexpressed when amplified. Willis et al. (2003) used an oligonucleotide chip to study mRNA from 12 breast tumours and two cell lines also typed using comparative genomic hybridization. A total of 20 known genes showed significant overexpression in tumours with gains of region 17q12-23; these included ERBB2, GRB7, PPARBP, and also MLLT6, KRT10 and TUBG1, which were not identified in our signature. In the study of Wilson et al. (2002) using a microarray with B5.000 cDNAs, only few genes from 17q were among those upregulated genes; these included RPL19 and LASP1. Dressman et al. (2003) studied 34 tumours and established a gene expression signature specific of ERBB2 þ samples that contained several 17q genes including GRB7, NR1D1, PSMB3 and RPL19. Sorlie et al. (2003) have also defined ERBB2 þ signature with five genes from 17q12, including ERBB2, GRB7 and PPARBP. Taken together, these reports indicate that genes located in the vicinity of ERBB2 are frequently coupregulated following DNA amplification. Some of the genes close to ERBB2 and present on our microarray did not appear in our signature, whereas they were found upregulated in other studies (i.e. LASP1, MLLT6). This may be due to a different proportion of tumours with variably sized amplicons in the analysed panels.
While amplification of region 17q12-21 affects ERBB2 chromosomal neighbours, ERBB2 protein overexpression will affect downstream targets and possibly also upstream regulators via positive feedback regulatory mechanisms. Balance in cadherins and integrins and functional processes associated with cell-matrix adhesive systems seem particularly affected in ERBB2-positive tumours (Wilson et al., 2002; this study) . This suggests that ERBB2 oncogenic activity may be associated with cell motility, as has been proposed previously (Tan et al., 1997; Spencer et al., 2000) . A recent study, using DNA microarrays, containing B6000 unique genes/ESTs, has described the transcriptional changes associated with a series of 61 genes following overexpression of a transfected ERBB2 gene in a mammary cell line (Mackay et al., 2003) . Previously, several studies had identified genes whose transcription is affected by ERBB2 overexpression or amplification using differential screening (Tomasetto et al., 1995; Oh et al., 1999) . Some of these genes are located near the ERBB2 locus. Our GES shares no common gene with the list of Kumar-Sinha et al. (2003) established in comparing cell lines including ERBB2-transfected cell line; however, a gene related to fatty acid biology, FADS2, is part of our signature. Tiwari et al. (1991) reported a relationship between ERBB2, fatty acids and 2 0 ,5 0 oligoadenylate synthetases (OAS2), which is included in our 'ERBB2 cluster'. Peroxisome proliferator-activated receptors (PPARs) are known regulators of lipid metabolism; their trans-activating capacity depends on the recruitment of auxiliary proteins (for a review, see Gilde and van Bilsen, 2003) ; modifications of fatty acid metabolism in ERBB2 þ tumours may thus be simply associated with overexpression of PPARBP.
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ERBB2 signature and assessment of ERBB2 status
The determination of ERBB2 status is important in breast cancer management, but is difficult in routine clinics since both IHC and FISH have limitations and are influenced by many variables (for recent reviews, see Rampaul et al., 2002; Bilous et al., 2003) . In routine practice, IHC, which more than FISH detects the actual target of Herceptint, is faster and more economic but highly dependent on fixative conditions, staining procedures, scoring system, quality controls and interlaboratory standardization. In addition, results are often difficult to interpret since a number of cases show only moderate overexpression of the protein and discrepancies in the results are subject to interobserver variability. In contrast, FISH method is reliable, quantitative and sensitive (Press et al., 2002) , but is also expensive, time consuming and requires specialized expertise and equipment. Finally, PCRbased methods are not reliable enough (Ginestier et al., in press ). As a consequence, there is still no consensus on the best method for assessing ERBB2 status. In this study, we report the potential of gene expression profiling to establish ERBB2 status, and to identify among ERBB2 2 þ cases, those with gene amplification and those without. These observations need confirmation on larger series of tumours, notably for ERBB2 2 þ samples. Nevertheless, the results in favour of gene expression profiling are encouraging and will require comparative studies to other methods (van de Vijver, 2002) . Currently however, DNA microarray testing is not designed to be used in a routine setting. It requires sophisticated technology and is expensive. These aspects, as well as standardization, will also have to be taken into account during the necessary validation of a gene expression-based approach prior to acceptance for routine clinical application. However, in the near future, biochip specifically engineered to suit the needs and requirements of a hospital-based platform may be an interesting alternative method for establishing simultaneously in one test not only ERBB2 status but a series of parameters for breast cancer management. Another important next step will be to identify a GES able to predict response to trastuzumab, and to compare it with the one described here.
In conclusion, we have identified a GES that can accurately identify ERBB2 alteration in breast tumours, as well as provide interesting clues to enhance current understanding of the role of ERBB2 in mammary oncogenesis. Its validity is reinforced by the iterative procedure of identification that we have used, its successful validation on two independent series of breast cancer samples and the identity of certain genes that were further validated at the protein level. This signature contains genes that are neighbours of ERBB2 on 17q12, and includes potential regulators and/or downstream effectors of ERBB2 (GATA4) and eventual targets (cadherin, integrins). It may be used both for breast cancer management in clinical settings and as a research tool in academic laboratories.
Materials and methods
Breast carcinoma samples
Using DNA microarrays, we studied 213 breast cancer samples obtained from women treated at the Institut Paoli-Calmettes between 1988 and 2001. Inclusion criteria of samples were: (i) sporadic primary breast cancer treated with surgery, (ii) tumour material quickly dissected and frozen in liquid nitrogen and stored at À1601C. Exclusion criteria included locally advanced or inflammatory or metastatic forms. The main characteristics of patients and tumours are listed in Table 3 . Immunohistochemical parameters collected included ER, progesterone receptor (PR) and P53 status (positivity cutoff values of 1%), and ERBB2 status (0-3 þ score as illustrated by the HercepTest kit scoring guidelines). All ('validation' set) . A consecutive series of 552 women with localized invasive breast carcinomas treated at the Institut Paoli-Calmettes between 1981 and 1999 was studied using a first TMA (TMA1). Of the 552 cases studied, 257 were available for ERBB2, GATA4, ER and Ki67 staining. According to the WHO classification, there were 194 ductal, 26 lobular, 10 tubular, three medullary carcinomas and 24 other histological types. The median age at diagnosis was 60 years, median age 60 years (range 25-91). A total of 135 tumours were associated with lymph node invasion, and 199 were positive for ER. A set of 94 tumours (chosen within those analysed by DNA microarrays and included in the learning set) was included in a second TMA (TMA2).
Breast tumour cell lines
Except for SUM-52, SUM-102 and SUM-149 (a gift of SP Ethier, Ann Arbor, MI, USA; http://www.cancer.med.umich.edu/breast_cell/clines/clines.html), the breast cancer cell lines (BT-474, HCC38, HCC1395, HCC1569, HCC1937, MDA-MB-157, MDA-MB-231, MDA-MB-453, SK-BR-3, SK-BR-7, T-47D, UACC-812, and ZR-75-1) were obtained from ATCC (Rockville, MD, USA; http://www.atcc.org/). All cell lines were grown according to the recommendations of the supplier.
RNA extraction
Total RNA was extracted from frozen tumour samples and cell lines by standard methods using guanidinium isothiocyanate solution and centrifugation on caesium chloride cushion as previously described (Theillet et al., 1993) . RNA integrity was controlled by electrophoresis on agarose gels and by Agilent analysis (Bioanalyzer, Palo Alto, CA, USA) before labelling.
Construction of DNA microarrays
DiscoveryChip DNA microarrays were prepared in our core facility (Ipsogen, Marseille, France; http://www.ipsogen. fr/). PCR products from a total of 9038 Image clones and hundreds of control clones were spotted on 12 Â 8.5 cm 2 nylon filters with a Microgrid II robot (Biorobotics Apogent Discoveries, http://www.apogentdiscoveries.com/BioRobotics.asp). Image clones represented 3910 ESTsEST and 5125 known genes, B3000 of which were related with oncogenesis. Control clones included poly(A) þ stretches, plant cDNAs and PCR controls. Microarray spotting was performed as previously described (Bertucci et al., 2000) .
DNA microarray hybridisations, data analysis and statistical methods
Hybridisations of microarrays membranes were carried out with radioactive [a-
33 P]dCTP-labelled probes made from 5 mg of total RNA from each sample according to described protocols (http:/tagc.univ-mrs. fr/pub/Cancer/). Membranes were then washed, exposed to phosphor-imaging plates and scanned with a FUJI BAS 5000 machine. Signal intensities were quantified with ArrayGauge software (Fuji, Du¨sseldorf, Germany), normalized for amount of spotted DNA and the variability of experimental conditions using nonlinear rank-based methods (Sabatti et al., 2002) , then log-transformed. We first applied supervised analysis to identify the optimal set of genes that best discriminated between ERBB2-negative and -positive breast cancer samples. The positivity cutoff of ERBB2 status was defined by protein expression using IHC (HercepTest kit, Dako Corporation, Copenhagen, Denmark): positive status was defined as 3 þ and negative status as 0 or 1 þ . Analysis was carried out in two steps: the molecular signature was first derived through training on the learning set of 145 samples including 116 ERBB2À and 29 ERBB2 þ cases; samples with ERBB2 status 2 þ (n ¼ 10) or unavailable (n ¼ 4) were not included in the supervised analysis. The signature was then validated on the validation set of 54 samples including 46 ERBB2À and eight ERBB2 þ cases.
ProfileSoftwaret Corporate (Ipsogen, Marseille) was utilized for all analyses. This program uses a discriminating score (DS) (Golub et al., 1999) combined with iterative random permutation tests. The DS was calculated for each gene as DS ¼ (M1-M2)/(S1 þ S2), where M1 and S1, respectively, represent mean and s.d. of expression levels of the gene in subgroup 1 (ERBB2 positive), and M2 and S2 in subgroup 2 (ERBB2 negative). Statistical confidence levels were estimated by bootstrap resampling as previously described (Magrangeas et al., 2003) with a false positive rate of 2/ 10 000. The program allows the identification of a molecular signature as independent of the sample set used as possible. Briefly, approximately two-thirds (n ¼ 106) of the samples from the learning set (n ¼ 145) were randomly selected to include at least 20 ERBB2 þ cases. They were then submitted to supervised analysis described above. The process was repeated 30 times (30 randomly defined subgroups of 106 samples), thus generating 30 lists of genes. These lists were then compared and a gene was considered as discriminator if present in at least 25 gene lists out of 30, allowing the identification of the most relevant genes, independent of the sample set used.
Unsupervised hierarchical clustering was applied to investigate relationships between samples and relationships between genes identified by supervised analysis. The hierarchical clustering was applied to data log-transformed and mediancentred on genes using the ProfileSoftwaret Corporate program (Ipsogen, Marseille) (average linkage clustering using uncentred Pearson correlation as similarity metric) and results were displayed with the same program.
Construction of tissue microarrays
Two TMA, TMA1 (552 samples) and TMA2 (94 samples), were prepared as described (Richter et al., 2000) with slight modifications (Ginestier et al., 2002) . For each tumour, a representative tumour area was carefully selected by histopathological analysis of a haematoxylin-eosin-stained section of a donor block. Core cylinders (one for each tumour for TMA2 and three for each tumour for TMA1), with a diameter of 0.6 mm for TMA1 and 2 mm for TMA2, were punched from this area and deposited into a recipient paraffin block using a specific arraying device (Beecher Instruments, Silver Spring, MD, USA). In addition to tumour tissues, the recipient block also included normal breast and established breast tumour cell lines to serve as internal controls: BT-474 known to have fourto eight-fold amplification of the ERBB2 gene, and MCF7, whose chromosomes 17 have each one copy of the ERBB2 gene. Sections (5 mm) of the resulting array block were mounted onto glass slides and used for IHC (TMA1) and FISH (TMA2) analyses.
Antibodies
The following antibodies were used for IHC: polyclonal antibody anti-ERBB2 (Dako-HercepTestt), used strictly following the guidelines described by the manufacturer; goat polyclonal antibody anti-GATA4 (sc-1237, 1 : 50 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-MIB1/Ki67 (1 : 100 dilution, Dako), anti-ER (clone 6F11, 1 : 60 dilution, Novocastra Laboratories).
Immunohistochemistry
IHC was done on 5-mm sections of TMA1. Briefly, tissues were deparaffinized in Histolemon (Carlo Erba Reagenti, Rodano, Italy) and rehydrated in graded alcohol. Antigen retrieval was carried out by incubation at 981C in citrate buffer. Slides were transferred to a Dako autostainer, except for Dako-HercepTestt where guidelines are imposed by the manufacturer. Staining was carried out at room temperature as follows: after washes in phosphate buffer, endogenous peroxidase activity was quenched by treatment with 0.1% H 2 O 2 , slides were preincubated with blocking serum (Dako Corporation) for 10 min, then incubated with the affinity-purified antibody for 1 h. After washes, slides were incubated with biotinylated antibody against rabbit IgG for 20 min followed by streptadivin-conjugated peroxidase (Dako LSAB R 2 kit). Immunoreactive complexes were visualized with the peroxidase substrate, diaminobenzidine, counterstained with haematoxylin, and coverslipped using Aquatex (Merck, Darmstadt, Germany) mounting solution. Slides were evaluated under a light microscope by three pathologists (ECJ, JH, JJ).
Immunoreactivities for GATA4 and ER were classified by estimating the percentage (P) of tumour cells showing characteristic staining (from undetectable level or 0%, to homogenous staining or 100%) and by estimating the intensity (I) of staining (weak staining or 1, moderate staining or 2, strong staining or 3). Results were scored by multiplying the percentage of positive cells by the intensity, that is by the socalled quick score (Q) (Q ¼ P Â I; maximum ¼ 300). For Ki67, only the percentage (P) of tumour cells was estimated, since intensity does not vary and for ERBB2, the status was defined using the Dako scale. Expression levels allowed to group tumours in two categories: no expression (Q ¼ 0 for GATA4 and ER, Po20 for Ki67 and 0/ þ for ERBB2), and expression (Q40 for GATA4 and ER, PX20 for Ki67 and 2 þ /3 þ for ERBB2). The average of the score of a minimum of two core biopsies was calculated for each case of TMA1. The reliability of the method was assessed by comparison with conventional sections for the usual prognostic parameters (including ER and ERBB2); the value of the kappa test was 0.95 (Ginestier et al., 2002) .
ERBB2 gene amplification detected by FISH
FISH for ERBB2 gene amplification was performed on TMA2 using the Dako ERBB2 FISH PharmDXt Kit, according to the manufacturer's instructions. In brief, TMA2 sections were baked overnight at 551C, deparaffinized in Histolemon (Carlo Erba Reagenti, Rodano, Italy), rehydrated in graded alcohol and washed in Dako wash buffer. Slides were pretreated by immersion in Dako pretreatment solution at 971C for 10 min and cooled to room temperature. Slides were then washed in Dako wash buffer and immersed in Dako pepsin at room temperature for 10 min. Pepsin was removed with two changes of wash buffer. Slides were dehydrated in graded alcohol. HER2/CEN17 (centromere 17) (10 ml) Probe Mix (Dako) was added to the sample area of each section. Sections were coverslipped and the edges were sealed with rubber cement. Slides were placed on a flat metal surface and heated at 821C for 5 min to codenature the probe and target DNA, and transferred to a preheated humidified hybridization chamber to hybridize the probe and DNA for 18 h at 451C. After hybridization, the rubber cement and the coverslips were removed from the slides. Sections were washed in wash buffer at 651C then at room temperature. Slides were dehydrated in graded alcohol and air-dried in the dark. Nuclei were counterstained with 15 ml of DAPI/antifade and coverslipped. Slides were stored at À41C in the dark for up to 7 days prior to analysis.
FISH scoring
Sections were examined with a fluorescent microscope (ZeissAxiophot) using the filter recommended by Dako. The invasive lesion selected for the TMA2 was easily localized under the microscope. Approximately 40 malignant, nonoverlapping cell nuclei were scored for each case, and included and scored only if HER2 and CEN17 signals were clearly detected. A ratio of HER2/CEN17 was calculated for each specimen that met this inclusion criteria. ERBB2 was considered as amplified when the FISH ratio HER2/CEN17 was X2.0. Each assay was read twice by two observers. Specimens were considered negative when less than 10% of tumour cells showed amplification of ERBB2.
Statistical analysis
Correlations between hierarchical clustering-based tumour groups and molecular and histoclinical parameters were investigated by using the w 2 test. Distributions of molecular markers analysed by TMA1 were compared using Fisher exact test. All P-values were two-sided at the 5% level of significance.
